1) Meltzer H et al. Am J Psychiatry 2011;168:957-67
2) Loebel A et al. Schizophr Res 2013;145(1-3):101-9
3) Nakamura M et al. J Clin Psychiatry 2009;70:829-36
4) Ogasa M et al. Psychopharmacol [Berl] 2013;225(3):519-30
5) Nasrallah H et al. J Psychiatric Research 2013;47(5):670-7
6) Citrome L et al. Int Clin Psychopharmacol 2012;27:165-76
7) Company Core Data Sheet (Table 4).
8) Murthy et al. Lurasidone for the treatment of schizophrenia: pooled analysis
of short-term, placebo-controlled trials (Abstract presented at ECNP, 8 October 2013)
9) Lieberman J.A. et al. Lurasidone in the treatment of early-stage
schizophrenia: a post-hoc analysis of three pooled acute treatment studies (Abstract
presented at ECNP, 8 October 2013)
10) Pikalov A et al. Eur Neuropsychopharmacol 2012;22(Suppl 2):S340
11) McEvoy J.P.et al. Switching to lurasidone in patients with schizophrenia:
tolerability and effectiveness at 6 weeks and 6 months (Abstract presented at ECNP, 8
October 2013)
12) Healy D et al. Mortality in schizophrenia and related psychoses: data from
two cohorts, 1875-1924 and 1994-2010. BMJ Open 2012;2:e001810
13) Chang C-K et al. Life Expectancy at Birth for People with Serious Mental
Illness and Other Major Disorders from a Secondary Mental Health Care Case Register in
London. PLoS One 2011;6:e19590
14) Laursen TM. Life expectancy among persons with schizophrenia or bipolar
affective disorder. Schizophr Res 2011;131:101-4
15) Tiihonen J et al. 11 year-follow up of mortality in patients with
schizophrenia: a population-based cohort study (FINN11 study). Lancet 2009;374:620-7
16) Lewis DA and Lieberman JA. Neuron 2000;28:325-34
17) Faries DE et al. Clinical and economic ramifications of switching
antipsychotics in the treatment of schizophrenia. BMC Psych 2009;9:54
18) Tsutsumi C et al. The evolution of antipsychotic switch and polypharmacy in
natural practice - A longitudinal perspective. Schizophr Res 2011;130:40-6
19) Salize HJ et al. Cost of schizophrenia in six European countries. Schizophr
Res 2009;111(1-3):70-7
20) Mangalore R and Knapp R. Cost of schizophrenia in England. J Ment Health
Policy Econ 2007;10(1):23-41
21) Zeidler J et al. The costs of schizophrenia and predictors of
hospitalisation from the statutory health insurance perspective. Health Econ Rev
2012;2(1):9
CONTACT: Media ContactsSunovion Europe Media ContactsStephanie Snow+44 7747 636 838stephanie.snow@munroforster.comEmily Ko+44 7513 037066emily.ko@munroforster.comTakeda Media ContactsElissa JohnsenTakeda Pharmaceuticals International GmbH+1 224 554 3185elissa.johnsen@takeda.comRed Door Communications+44 7787 643964cgrindal@rdcomms.comMedia Contacts in Japan:Dainippon Sumitomo Pharma Co., Ltd.Corporate Communications Dept.Phone: +81-6-6203-1407 (Osaka), +81-3-5159-3300 (Tokyo)Takeda Pharmaceutical Company LimitedCorporate Communications Dept. (PR/IR)Phone: +81-3-3278-2037
